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Workshop Discussion and Focus
A wide range of professionals and representatives from lay
support groups met to address the ‘‘Burden of Skin
Disease’’ in a meeting hosted by the National Institute of
Arthritis and Musculoskeletal and Skin Diseases (NIAMS) in
September 2002. Proceedings from the meeting were trans-
cribed and are summarized herein. Recommendations were
developed addressing the burden of skin disease in the
United States and will be the basis of an initiative to
encourage additional research and development related to
this important issue.
The burden of skin disease represents more than just the
economic burden and may not be measured by classic
morbidity or mortality data. Rather, it represents the overall
influence of skin disease on patients (including quality of life
issues), their families and society (Barendregt et al, 1997;
Murray and Lopez, 1997; Lopez and Murray, 1998). There
is a relative (almost absolute) lack of data for most of these
burdens and, more importantly, a deficiency of valid instru-
ments to measure them at this time.
Traditional measurements of the burden of skin dis-
ease There is no single number or quantitative estimate,
mathematical equation, or ratio that can summarize the burden
of skin disease precisely or intuitively. The two main issues are:
1. How is skin disease defined?
2. How do we define the burden of skin disease?
Although the skin is a well-defined organ, it can be
primarily or secondarily involved in a number of systemic
conditions. Hence, the definition of skin disease remains
ambiguous. Additionally, there is no consensus on terminol-
ogy for coding skin disease. Definitions for skin disease will
enhance an acceptable taxonomy system.
To approach a precise definition of skin disease, there
must first be agreement on the names for skin disease.
Currently the Dermatology Lexicon Project sponsored by
NIAMS and the Carl J. Herzog Foundation is focusing on
this problem and will have recommendations available
soon. Another prerequisite is consensus among dermatol-
ogy investigators and other professionals on methods for
analyzing data on clinical outcomes. Let us consider a study
of mortality resulting from melanoma as an example. Data
are obtained from the National Death Index (NDI). The data
for NDI come from death certificates on which physicians
document a cause of death. If the patient died because of a
massive stroke in turn caused by melanoma metastases,
then the cause of death could be documented as melanoma
or stroke (Freedman et al, 2002). If it were the latter, deaths
resulting from melanoma would be missed. Despite these
limitations on the manner in which causes of mortality are
classified and defined, mortality at least is a reliable clinical
outcome because it is an all or nothing phenomenon (Severi
et al, 2000; Geller et al, 2002). Nevertheless, few skin
diseases are a direct cause of mortality.
Similarly, ‘‘incidence’’ is an important measure, usually
expressed as an age-adjusted rate of the number of new
cases of a particular disease or condition per a unit of time.
Incidence rates have been presented in several ways, for
example, in relation to geographic location or body site
(Mathers et al, 2002). For malignancies, the SEER registries
maintained by the National Cancer Institute since the 1970s
are an important resource that provide data on the
incidence of melanoma (Shaw et al, 1977). The drawback
from a burden of skin disease perspective is that SEER
does not include information on nonmelanoma skin cancer.
The ‘‘prevalence’’ of skin disease is another example of
a frequently used point estimate. Prevalence takes into
account a specific period of time over which new cases
developed. It provides a more accurate and representative
estimate of disease burden for chronic conditions. For
example, prevalence of melanoma may underestimate the
burden of this potentially life-threatening malignancy if
patients with melanoma die soon after being diagnosed.
On the other hand, incidence of psoriasis, that is, new cases
of psoriasis per year, may underestimate the burden of this
chronic inflammatory condition that is better captured by
prevalence.
In contrast to mortality, incidence, and prevalence mea-
sures, the concept of ‘‘years of potential life lost’’ is compu-
ted in a number of different ways. One government agency
may count years of life lost by estimating how much an
individual’s life expectancy is reduced by an illness. Another
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government agency may compute the number of years of
life lost as an individual’s years until mortality up to the age
of 65 y (those formally being the productive years of life).
This can result in very different answers for relative ranking
of diseases by years of potential life lost.
There is a trade-off between making an attempt to
summarize facts into a single number versus retaining their
richness and information content. The results of the global
burden of disease, as assessed initially by the World Bank,
indicated that the burden of skin disease was relatively
unimportant in all countries, regardless of income level.
Approximately 1/10th of 1% of overall ‘‘burden’’ is attribu-
table to melanoma, and approximately 1/10th of 1% of
burden is due to other skin diseases. There has been
widespread criticism of such an analysis among both
economists and physicians and the face validity (whether
the data makes sense at first glance) and content validity
(whether the data address the question being asked) of the
data have been questioned.
In this context, the Onchocerciasis Control Program
(OCP) dramatically illustrates how the burden of skin
disease is often underestimated (Benton et al, 2002). The
OCP is a collaborative program implemented in 11 West
African countries, initiated by the World Bank in collabora-
tion with the World Health Organization. A complication
of the disease onchocerciasis is ‘‘River Blindness,’’ and the
original concern was that loss of vision in a worker
dependent on daily wages in a developing country would
lead to major economic consequences. The economic
impact is due to both the disability for the patient and the
large areas of fertile land lying unused because of the risk of
infection in endemic areas. After about 25 y of a sustained
effort and careful economic analysis of benefits versus
costs, one of the striking findings that emerged from the
analysis was that although blindness was indeed important
to patients, a major concern of the people who had been
in the endemic region was the cutaneous complications of
onchocerciasis including both severe itching and the long-
term social consequences, because women who had been
seriously affected could not marry because of skin-related
problems. Thus, the cutaneous complications were sub-
stantially more important than the visual consequences in
the lives of the people affected by the disease and to the
beneficiaries of the control programs.
The message is that a single number or estimate cannot
capture the true burden of skin disease. The challenges are
to make sure that the goals of the measurement are clear,
that the tools being used to gather data are reliable and valid
for the population being studied, and that improvements are
constantly being made to extend the analyses. Nomenclature
for skin disease needs to be agreed upon and adopted as a
standard. Once a standard is established, health services
research can be conducted using standardized codes for
disease categories, generating more reliable estimates for
incidence or prevalence. These numbers or estimates can
then be incorporated into matrices that will allow for priority
setting exercises in terms of health policy development.
Novel concepts of burden of skin disease and its impact
on society Public and congressional interest in the burden
of disease stems from the trade-off between health burden
(impact of illness on functional status of the individual and
society) and cost burden (impact of illness on economic
status of individual and society) (Atherly et al, 2000; Brown
et al, 2000). Funding of research efforts can have an impact
in this trade-off, by allowing interpretation of findings and
informed priority setting (Freedberg et al, 1999). Both
the health burden and the cost burden are important to
consider when planning such research efforts. Rising costs
with little additional benefit are detrimental to the health-
care delivery system. The purpose of measuring the overall
burden of skin disease is to eventually focus on serious
dermatologic conditions that have been previously:
1. Considered merely cosmetic in nature and hence
allocated less research funding; or
2. Deemed less of a burden compared to a noncutaneous
disease and hence also provided less attention at the
policy level.
The burden of skin disease, or of any disease, must be a
multidimensional concept, including the adverse impact of
skin disease on economic factors, on length of life, and on
various dimensions or domains of health, including physical
health, psychological health, and social functioning. It in-
cludes impairments or pain, and it includes health percep-
tions of well-being, concern, or worry. How does disease
impact society? How many and who are affected? What
happens to their disease and the prognosis of their
disease? What happens to them as individuals and how is
their lifestyle affected? Can we measure the resulting job
changes or losses, for example, and burden on society or
on an individual as a result of losing that worker or that job?
How much does it all cost?
A reliable and valid summary measure(s) of health and
disease is needed. A theoretical ratio or mathematical
comparison between ‘‘good’’ health on one end of the
spectrum and ‘‘bad’’ health at the other extreme would
constitute a single estimate of the burden of disease. The
limitations of trying to define the concept of ‘‘burden of
disease’’ have been discussed and such endeavors may
not fully capture the essence of this concept, factually or
philosophically (Gold and Muennig, 2002).
Addressing this novel and complex concept of ‘‘burden
of skin disease’’ forces us to address a number questions
simultaneously:
1. What are the elements that comprise the burden of skin
disease?
2. What is the impact of these elements on public health
and daily living?
3. What are current data collection instruments and can
they be improved?
4. What kind of data collection instruments will be needed
to facilitate the collection of future data, and what data
will we need in the future?
The burden of cost of care is a recently developed but
well accepted and validated metric (O’Brien and Briggs,
2002). Nevertheless, other factors that contribute to the
overall well-being of patients with skin disease, such as
personal and family issues, education, relationships, quality
of life, and societal and social functioning, have not been
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the focus so far. It is the purpose of this report to bring to the
attention of policy makers and researchers, several areas of
potential research in skin disease that require more rigorous
study.
Available quality of life and other measurement instru-
ments There are two overall approaches to assessing
health-related quality of life. One involves global measures
that integrate all aspects of quality of life such as social,
mental, and physical well-being and provide a single
number as an estimate. A disadvantage of this method is
that a score of 0.60 gives little information about the ways in
which a respondent’s quality of life might be affected; an
individual who is very physically impaired may have an
identical score to one who is mentally impaired. The other
method uses evaluation-oriented approaches. This method
produces multiple scores for various subscales or domains,
for example, a score for mental health, another for physical
health, or body image or anxiety.
The patient’s perspective of the burden of skin diseases
is critical; because skin diseases rarely affect survival but
often alter appearance and affect function (Kurwa and
Finlay, 1995), they can affect patients’ lives in complex
ways, especially in emotional and functional domains.
Patients’ estimates of quality of life often correlate poorly
with clinicians’ estimates of the severity of a disease.
Health-related quality-of-life measures can also be
classified as general or disease-specific (Table I) (Harlow
et al, 2000; Levine and Ganz, 2002). Skin disease is not a
single condition, but symptoms may be common to a
number of conditions. Therefore, a general instrument can
generate responses from any patient with a skin condition,
whereas disease-specific quality-of-life measures are best
suited for evaluating a patient’s experience of a particular
disease (Dijkers, 2003; Wiebe et al, 2003). Although not
particularly sensitive to skin-specific domains, general
quality-of-life measures have the advantage of providing
estimates that can be compared across multiple diseases in
the same specialty or in primary care or to compare
dermatologic with nondermatologic diseases (examples
include the medical outcomes short form (SF-36) and the
sickness impact profile (SIP)). In addition to looking at
health-related quality of life, economic burden (O’Hagan
and Stevens, 2002) and—importantly—patient satisfaction
can also be measured. The goal is to use a measure that
can access the areas of most interest to the researcher and
one that will be sensitive to change.
Skin-speciﬁc quality-of-life indices Examples of two com-
monly used skin-specific quality of life indices are the
dermatology quality-of-life index (DLQI) (Finlay and Khan,
1994; Finlay, 1998) and Skindex. The DLQI (described in
more detail elsewhere in this issue of the journal) was
developed in the United Kingdom and has 10 items that
address a variety of quality of life aspects. A single score is
generated, varying from 0 to 30 (30 being the poorest
quality of life). Skindex, developed on the United States, is
available in a longer (29-item) and shorter (16-item) version.
Responses to Skindex are reported as subscale scores for
symptoms, emotions, and functioning. Skindex scores vary
from 1 to 100 (100 being poorest quality of life).
Some additional examples of disease-specific quality of
life measures in dermatology are the Psoriasis Disability
Index, the Acne and Eczema Disability Index, the Acne
Specific Questionnaire and other acne indices (Lasek and
Chren, 1998) and Scalpdex (Chen et al, 2002). Ongoing
work on evaluating patient preferences (utilities), emphasiz-
ing the patients’ roles in their own health care, are related to
but distinct from quality of life measures and have been
demonstrated to be feasible in dermatology patients.
Nontraditional measures of burden of skin disease Qualita-
tive research can also provide rich data about the burden of
skin disease, particularly data that permit us to understand the
complexities of this burden. For example, 10,000 e-mail mes-
sages were analyzed from 225 adults in an Internet support
group for patients with eczema (presented by S. Diamond,
San Francisco, CA). The results documented a broad range of
quality-of-life effects including frequent incidents of shunning
and outright discrimination, generalized anxiety, and pessi-
mism regarding all intimate relationships. There were also
specific fears of rejection and being considered unacceptable.
The disease had an influence on family planning choices; the
decision to bear children was affected by concerns about a
possible child developing atopic dermatitis.
These results amplify typical results from quantitative
studies of quality of life of specific diseases (Liakopoulou
et al, 1997; Williamson et al, 2000): The physical, social, and
emotional consequences of skin diseases are myriad
and substantial. A quality-of-life study was performed on
alopecia areata patients from 1994 through 1997 and a
disease-specific questionnaire was validated. Approxi-
mately 740 questionnaires were distributed, 200 subjects
responded, and the majority of the respondents were
women (presented by Dr W. Bergfeld, Cleveland, OH).
Body image, distortion, worry, patient expectations, poor
attitude toward the present treatment, and discomfort about
a diagnosis were found to be the major associations.
Clinical depression was seen in all age groups. Disease-
specific instruments can be used in further studies involving
patients with alopecia areata.
An innovative example of a data collection vehicle that is
not on paper or performed by an interview focused on a
group of asthma patients who had been provided with video
cameras. The videotapes they produced of their lives with
asthma were used by multidisciplinary teams of physicians
and psychologists to learn what that particular individual finds
problematic in their life while living with this chronic illness.
From the perspective of the National Psoriasis Founda-
tion (presented by T. Rolstad, National Psoriasis Founda-
tion), the spectrum of burden of psoriasis again involves
multiple quality-of-life domains including physical limita-
tions from the disease, external limitations imposed on the
individual by others, and emotional and psychosocial
limitations. The physical limitations are experienced cer-
tainly most, but not exclusively, by people with moderate to
severe psoriasis, which is about 1.5 million people in the
United States. Severe itching, skin pain, swelling, and sleep
deprivation are commonly experienced symptoms that
cause significant quality-of-life problems. Plaques on the
hands or feet, although they may not cover much of the
body surface area, can prevent people from being able to
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Table I. A brief list of available health-related quality-of-life (HR-QOL) instruments
Instrument Reference Salient features
Dermatology-speciﬁc
issues
Generic instruments
EuroQoL (EQ-5D) Brooks et al (1996) Simple instrument to administer 5 health dimensions
addressed on a three-category response scale
Typically used in cost-utility
evaluation
Principal question is a 20-cm vertical Visual Analog
Scale
Nottingham Health of Profile
(NHP)
Hunt et al (1981) More focused on feelings and emotions rather than
behavior change (as in SIP)
Main focus is on genetics
and immunology of
psoriasis
38 items, 6 health dimensions
No single summary index
Patient Generated Index (PGI) Ruta et al (1994) Based on patient nominated aspects of life that are
then scored according to severity
Can be used as general QOL
measures
PGI scores items on a 0–10 scale
SEIQoL scores items on a vertical Visual Analog Scale
Schedule for Evaluation of
Individual Quality of Life
(SEIQoL)
Hickey et al (1996)
Short Form-36 (SF-36) McHorney et al (1993) Widely used generic HR-QOL instrument Can be used as a general
QOL measure
Items chosen from larger dimension-specific instru-
ments used in Rand Medical Outcomes Study
36 items, 8 health dimensions
One global question about overall health
Sickness Impact Profile (SIP) Bergner et al (1981) Developed in the 1970s
Measures illness-related dysfunction
136 statements, 12 health dimensions
Interviewer- or self-administered Can be used as a
general QOL measure
Disease-specific instruments
Dermatology Quality of Life Index
(DLQI)
Finlay and Khan
(1994)
Skin disease-specific Has been evaluated in
various skin diseases
10 items, 6 health dimensions
European Organization for
Research and Treatment of
Cancer (EORTC) QLQ-C30
Aaronson et al (1993) Cancer-specific May have some use in skin
cancer research
30 items, 5 functional scales, 3 symptom scales
Global health-status-QOL scale and single items
assessing cancer-related symptoms such as
insomnia, constipation, etc.
Functional Assessment of Cancer
Therapy (FACT)
Cella et al (1993) Disease-specific instrument May have some use in skin
cancer research
FACT-G is the core instrument, part of the Functional
Assessment of Chronic Illness Therapy (FACIT)
29 items, 5 health dimensions
Pediatric Asthma Quality of Life
Questionnaire (PAQLQ)
Juniper et al (1996) Targeted to children aged 7–17 y with asthma
23 items, 3 health dimensions
One global question
Interviewer-administered version preferred
Rotterdam Symptom Checklist
(RSCL)
Smets et al (1996) Cancer focused May have some use in skin
cancer research
30 items on 4-point scales, a question about activity
level, a global question with seven categories
Skindexa Chren et al (1996) Skin disease-specific Has been evaluated in
various skin diseases
29 or 16 items; 3 scales
Self-administered
aSkin-disease-specific instruments.
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hold their children, work at a computer, or care for their
homes. Treatment may require clinic visits three or four times
a week, particularly for patients undergoing phototherapy. In
addition, self-care can take 1 h or more per day for many
people including bathing and application of topical ointments,
treatments, and moisturizers. External limitations that are
faced by people with psoriasis and many other skin diseases
include discrimination. Because of inappropriate questions of
contagion, patients are asked not to work in food service or
customer service positions or maybe prevented from taking
advantage of recreational opportunities, such as participating
in health clubs, swimming pools, or school sports.
All clinicians caring for patients with skin diseases can
attest to the fact that the effects of dermatologic disease on
patients are not captured by traditional measures (Gilbody
et al, 2002). Repeat testing may provide more reliable data
compared to a single evaluation. Hence, the emphasis on
the richness of the information obtained from quality-of-life
measurements (Chren et al, 1997) and, in this report, the
guarded skepticism about summary measures.
Available databases and data sets There are a number of
databases that have been generated either by purposeful
disease surveillance mechanisms (e.g., National Health and
Nutrition Examination Surveys) or as a by-product of the
health-care delivery system (e.g., billing and coding data
from the Centers for Medicare and Medicaid Services). A
few examples of national, population-based databases and
privately maintained, disease-specific databases are sum-
marized in Table II. The list is by no means complete but
serves as an introduction to a variety of databases available
for researchers.
Databases can be classified into four broad categories.
Administrative databases contain data that are collected for
administrative purposes, such as billing or scheduling.
Although administrative databases are created for a
nonresearch purpose, a great deal of information relevant
to burden of disease can be gleaned from them. Patient
record databases are compilations of information that are
meant to aid in patient care. The trend over the past few
years to create electronic medical records has allowed such
databases to be created. Registries can be incredibly
helpful to researchers in the health services arena since
these databases contain already identified or diagnosed
individuals of interest. Cross-sectional surveys can yield a
wealth of information that is usually of high quality, as it is
typically collected for research purposes.
Databases do have limitations because of the manner in
which data compilation is performed and the initial purpose
of data collection. Consistency and completeness of data
are important. Whether it is the economic burden and cost
of managing illness or the health-related aspects of burden
in terms of premature mortality and disability, data are not
always collected with research hypotheses in mind. Bearing
in mind some of these limitations, databases can be used to
obtain answers to research hypotheses of interest.
Workshop Recommendations
Novel approaches to deﬁning and evaluating the burden
of skin disease It is clear from existing evidence that more
work is needed in the patient-oriented research arena.
Creative approaches are needed to measure how much of
an impact skin disease can have on an individual or a
community. There is a natural tendency to use techniques
and strategies that have been created and validated in other
fields, which is reasonable as long as the overall approach
is also relevant to measurable outcomes in skin disease.
Nevertheless, this dilemma of burden of skin disease
measurement also creates a unique opportunity for ground-
breaking work in the development of measures specific to
dermatology. There are even fewer measurements looking
at the burden of skin disease in children, and this should be
kept in mind when designing new studies.
There are two mutually exclusive, but not collectively
exhaustive, categories of disease burden measurement that
the workshop participants felt should be addressed in future
research endeavors:
1. Cost-effectiveness studies, including issues of direct
costs, and productivity losses associated with the
disease (Emery and Schneiderman, 1989); and
2. Quality-of-life measures, including the social and emo-
tional impact of disease.
Using these approaches, data need to be collected in the
United States in large population studies. One option is to
collect disease-specific data using disease-specific instru-
ments, capturing the consequences and impact of a
specific condition. This option has the capacity to track
progress in the treatment or prevention of that condition.
Another option is to collect disease-specific data using
generic instruments that yield quantitative information that
can be compared to similar data from other disease-
specific analyses. Such comparisons can potentially be
used to inform a larger priority-setting exercise at a health-
policy level. One can make the argument that these two
methods of data collection are not alternatives and, in fact,
are complimentary.
Another approach would be to employ a combination of
measures, with the data-gathering vehicle composed of
multiple modules. Core modules would collect data that are
common to all areas of skin disease and disease-specific
modules would ask questions about a specific disease
type. A global skin disease quality-of-life instrument that is
not disease-specific could be matched with other disease-
specific instruments as chosen by individual investigators.
The combination of factors that affect quality of life can
be collectively referred to as the compounded burden of
disease. The variables that are of particular significance to
an individual, as well as the comprehensive burden, may be
immeasurable using standardized instruments. If the goal is
to have an impact on patient care, additional qualitative
tools must be used. As in the psychometric assessment
arena, such new measures or instruments that serve as data
collection vehicles will take some time to develop, test, and
validate.
How can one best quantitatively measure a qualitative
problem such like quality of life? First, a comprehensive
hypothesis or a conceptual framework for the effects of skin
disease on patients’ quality of life must be developed.
Second, questions or items that address all aspects of the
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hypothesized framework must be composed or borrowed
from other instruments that may test similar issues. Third,
the instrument must be pilot tested with patient responses
to determine the reliability, validity, and sensitivity to change
of the instrument. Finally, the instrument must be modified
based on the pilot data obtained before being used for data
collection.
A precedent for the type of overall measures proposed
may have already been set. In 2001, the National Cancer
Institute (NCI) undertook a major initiative to help establish a
core set of health-related quality-of-life cancer measures.
The goal was to improve comparability and to maximize the
usefulness of data collected. Thirty-five scientific experts
were assembled as the Cancer Outcomes Measurement
Working Group to assess the state of outcomes measure-
ment in cancer and identify priorities for future research and
practice. This group serves not as an advisory body or a
consensus panel, but provides input to define a core set of
outcome measures for health-related quality of life. In
addition, the group will eventually evaluate ways to measure
economic burden and patient satisfaction as well as the
continuum of care (Deffenbaugh, 1994). The latter ranges
from screening and prevention treatment to survivorship
and end-of-life issues. The group will also evaluate various
applications including patient and clinician decision-making
algorithms, clinical trials, observational studies, and popu-
lation monitoring, as well as reimbursement and policy
decisions.
As a variety of different measures are developed and
used to quantify various aspects of the burden of skin
disease, involvement of patient groups is pivotal to
demonstrate their confidence and trust for the research
endeavors to patients. The Coalition of Patient Advocates
for Skin Disease Research has an important view of future
research endeavors. Their intent is to examine the burden of
skin manifestations that relate to systemic involvement,
age, sex, disease severity, and psychosocial effects, with
the assumption that evaluating quality-of-life issues for an
individual in the context of the family and the community
would yield results more representative of the problem.
Because accurate measurement and integrated assess-
ment is needed, partnerships between patient groups and
surveillance entities, like government, academia, or indus-
try, can encourage patient participation and compliance.
Data collection and warehousing needs As noted, there
are unique challenges even in defining the term ‘‘skin
disease.’’ The definition is quite broad: Thermal burns,
eczema, and skin infections are all classified as skin
disease. Decubitus ulcers are also skin disease, but may
not be managed by dermatologists, and melanoma is
primarily considered an oncologic disease rather than a skin
problem. An even bigger challenge is that certain conditions
are not considered a disease per se, such as skin aging,
striae, and male pattern baldness. Also important to
consider is the perspective of society versus the perspec-
tive of the family or an individual, all of whom view the
burden of skin disease from a different angle.
Before large databases are planned, there needs to be
consensus on a nominative system for skin disease
categories to aid in coding. As previously noted, the
Lexicon Project will report its recommendations in the near
future. Multicenter initiatives that include investigators from
many disciplines are then needed to plan for creation of
large-scale prospective databases that are assembled at
the point of care, prospectively over time. Population-based
measures and studies will help measure the impact of
disease on the individual patient over a relatively short
interval, but a large sample size can help provide an
assessment about the state of the population.
It is important to realize that a registry is a kind of
database that allows investigators to perform prospective
studies on patients who have been identified with a
particular disease. In the classic sense, a registry is just a
list of names that enables other people to perform the
prospective studies, validate different instruments, use the
tissue samples that were obtained decades before, and
evaluate what happens to the patient after therapy.
A database or registry that is set up to measure burden
of skin disease in the United States will be faced with an
ethical dilemma. Should it be focused on a population-wide
approach to data collection or should it be focused on a
subset of the population that is at ‘‘high risk’’ for develop-
ment of the skin disease of interest. Ethical issues arise if a
large proportion of individuals who are equally high risk are
neglected if the mechanism to identify those at high risk is
inaccurate and unreliable. Investigators assembling data-
bases of this nature will be in the best position to resolve
this issue.
Costs for assembling a comprehensive database can be
extremely high. If databases are assembled for research
purposes, significant amounts of grant funding and partici-
pation of multiple centers or at least one large center is
necessary. If the research hypotheses target problems that
are relatively common in the source population, a relatively
small database may suffice. Nevertheless, when disease
trends are largely unknown, very large data sources with
very large numbers of people are needed if any conclusions
are to be drawn (Taylor, 2001). Once a database is available,
a range of study designs can be applied depending on the
nature of the research question, including cohort, nested
case-control, case-cohort, case-control, and cross-sec-
tional studies.
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